After 1 year of treatment, the PAH and PAH SDS were significantly higher in GnRHa monotherapy group than the GnRH + GH combination group (158.76 ± 5.29 cm vs. 154.52 ± 4.73 cm, − 0.42 ± 1.06 vs. − 1.29 ± 0.99, respectively P < 0.001). Here, GH1 is linked to pulmonary arterial hypertension.